Lupin has informed that Lupin Inc., USA, wholly owned subsidiary of the Company, has signed Definitive Agreement with Sunovion Pharmaceuticals Inc., USA for acquiring Brovana® and Xopenex HFA®, respiratory brands. In this regard, in compliance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the company has attached some particulars. It had also attached a Press Release in connection with the acquisition.
The above information is a part of company’s filings submitted to BSE.
